Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Alone or in Combination With Talazoparib or Axitinib in Endometrial Cancer
NCT02912572Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2016
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of avelumab in endometrial cancer (EC) (4 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Objective Response Rate up to 39 months and Progression-Free Survival at 6 Months. Started Nov 2016; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02912572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912572.